Article
Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Leukemia - 1 Mar 2018
Sidana S, Tandon N, Dispenzieri A, Gertz M A, Buadi F K, Lacy M Q, Dingli D, Fonder A L, Hayman S R, Hobbs M A, Gonsalves W I, Hwa Y L, Kapoor P, Kyle R A, Leung N, Go R S, Lust J A, Russell S J, Zeldenrust S R, Rajkumar S V, Kumar S K
Abstract excerpt
Hematologic response criteria in light chain (AL) amyloidosis require the difference in involved and uninvolved free light chains (dFLC) to be at least 5 mg/dl. We describe the clinical presentation and outcomes of newly diagnosed amyloidosis patients with dFLC <5 mg/dl (non-evaluable dFLC; 14%, n=165) compared with patients with dFLC ⩾5 mg/dl (evaluable dFLC; 86%, n=975). Patients with non-evaluable dFLC had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.